Latest News

Elevation Oncology Emerges from Stealth with $32.5M Series A to Develop Precision Medicines for Tumors Harboring Rare Genetic Driver Alterations

Elevation Oncology, a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today the launch of the Company with a $32.5M Series A financing, initiation of the Phase 2 CRESTONE study, and new partnerships with Next Generation Sequencing diagnostic providers including Ashion Analytics, Strata Oncology, and Tempus to explore innovative models for real-time identification, patient referral, and enrollment of patients with tumors driven by rare genomic alterations. The Series A financing was led by Aisling Capital and a syndicate of investors including Vertex Ventures HC, Qiming Venture Partners USA, Driehaus Capital Management, and BVF Partners.

21 Jul 2020
Read more

Investing in the future – Carolyn Ng on how global biotech and diversity will change our world

As Managing Director of Vertex Ventures HC located in the Bay Area, Carolyn Ng leads an investment team to fund healthcare-focused opportunities globally. Passionate about biotech innovation, diversity, and gender equality, the former oncology scientist shares how her Singaporean roots and cross-border expertise add valuable perspective to her work with companies and investors. She shares her view on how global biotech and diversity will change our world.

01 Jul 2020
Read more

Nuvaira Announces FDA Breakthrough Designation for AIRFLOW-3 Pivotal Trial Device

Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, has announced that its Nuvaira® Lung Denervation System has been designated as a Breakthrough Device by the U.S. Food and Drug Administration (FDA). This program creates an expedited pathway for prioritized FDA review of devices that have potential to provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.

08 Jun 2020
Read more

Bicycle Therapeutics: Announces First Patient Dosed in Phase I Dose Escalation of BT5528 in Combination with Nivolumab

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the first patient has been dosed in a Phase I dose escalation of BT5528 in combination with nivolumab. The Phase I trial includes both a monotherapy arm as well as a combination arm.

05 May 2020
Read more

Guest Article by our MD Carolyn Ng for the Timmerman Report: “Singapore’s COVID19 Crisis: Forgetting to Check the Blind Spot”

Despite being a densely populated high-risk state, Singapore managed to keep its cases extremely low. No deaths were reported between late January and mid-March. But even then, there were warning signs. In that same piece, I expressed concern for a potential second wave of cases that could be triggered by the massive influx of Malaysian foreign workers who rushed to enter Singapore before Malaysia closed its borders on Mar. 18. Interestingly, while Singapore did experience a second wave in late March, the new cases were not attributed to foreign workers. Most of the new cases were from Singaporeans returning home from travels to global hotspots such as the UK and US

22 Apr 2020
Read more

Vertex Ventures HC’s Jeff Schlosser’s invention won this year’s Gold Edison Award.

Walter is honored! The WalterLorenz® Surgical Assist Arm was recently awarded a Gold Edison Award™ in their Medical/Dental category for Advanced Surgical Instruments.

06 Apr 2020
Read more

Get In Touch

    Our Global Network

    Vertex Ventures HC is part of the global Vertex Ventures network of funds.

    In addition to the HC Fund, the Vertex Global Network is comprised of affiliates in Israel, China, Southeast Asia and India. Leveraging the combined experience and resources of our extensive partner network enables our portfolio companies to realize their full potential.


    © 2019 by Vertex Ventures

    All rights reserved.